Bruker

BRKR

Market cap $6.09B

ORLANDO, Fla.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced the launch of CellScape™ XR, a next-generation spatial proteomics platform designed to advance the development of diagnostic and prognostic assays by delivering unprecedented quantitative performance, robustness, and flexibility. CellScape XR addresses a critical bottleneck in translational research by enabling high-throughput, reproducible spatial proteomics at a scale and rigor required for translational and clinical.

ORLANDO, Fla.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Spatial Biology, a division of Bruker Corporation (Nasdaq: BRKR) announced today that it will expand its collaboration with Noetik Inc., following their prior study of more than 3500 patient samples with the CosMx® Spatial Molecular Imager (SMI). CosMx SMI powers Noetik's pre-training and scaling of bio-foundation models to perform complex genome-wide simulations of human cellular- and tissue-level biology to enable diverse therapeutics applications. “Noet.

ORLANDO, Fla.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today significant portfolio advancements from Bruker Spatial Biology to be unveiled at the 2026 Advances in Genome Biology and Technology (AGBT) General Meeting. These updates highlight Bruker's category leadership in spatial biology and its commitment to delivering best‑in‑class solutions across DNA, RNA, and protein. The Bruker Spatial Biology division will launch several new products, introduce expanded capabilities,.

ST. LOUIS--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced new advancements to enable Functional Proteomics 2.0 workflows on the timsOmni™ mass spectrometer to enable disease researchers to move beyond canonical protein lists toward biologically or pathologically functional proteoforms and PTM-resolved peptide variants. New releases in Bruker ProteoScape™, OmniScape™, and GlycoScape™ software now support database-independent PTM discovery, confident proteoform characterizatio.

Examine the evolution of Bruker's (BRKR) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

BRKR's Q4 EPS miss estimates as margins plunge and shares fall 2.7% despite a revenue beat, while the 2026 outlook targets 4%-5% sales growth.

Bruker Corp (NASDAQ: BRKR) reported mixed fourth-quarter financial results on Thursday.

Bruker Corporation (BRKR) Q4 2025 Earnings Call Transcript

While the top- and bottom-line numbers for Bruker (BRKR) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Bruker (BRKR) came out with quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.76 per share a year ago.